Mazindol ER is under clinical development by NLS Pharmaceutics and currently in Phase II for Narcolepsy. According to GlobalData, Phase II drugs for Narcolepsy have a 59% phase transition success rate ...

Hallucinations. Sleep paralysis. Excessive daytime sleepiness. Jenny Lee-Gilmore was diagnosed with Type 1 narcolepsy at 21 — ...

Model Lee Hyun-yi confessed that she was diagnosed with narcolepsy, a rare and intractable disease.According to the Health ...

Narcolepsy is a sleep disorder that affects the brain ability to regulate sleep-wake cycles and it can present unique challenges for adolescents Teenagers with narcolepsy experience symptoms like exce ...

Pitolisant hydrochloride is under clinical development by Bioprojet SCR and currently in Phase II for Autism Spectrum Disorder (ASD).

017). Topline results were announced from a phase 3 trial evaluating AXS-12 (reboxetine) in patients with narcolepsy. AXS-12 is an investigational highly selective potent norepinephrine reuptake ...

NEWARK, Del, Nov. 27, 2024 (GLOBE NEWSWIRE) -- The Narcolepsy Treatment Market 2024 to 2034 is expected to experience substantial growth, with the market size projected to expand from USD 5,301.6 ...

Jazz's neuroscience franchise faces declining Xyrem sales but sees growth in Xywav and Epidiolex. Oncology growth is driven ...

I feel myself weightless, but like I literally cannot move. I thought narcolepsy was what we saw on TV. I had no basis for understanding it, and I never done my own research to actually figure out ...

Axsome's AXS-12 met its primary endpoint in a Phase 3 study, significantly reducing cataplexy attacks in narcolepsy patients, positioning it for an NDA submission. The narcolepsy market is ...

Ginger Zee provided her fans with a brief health update after undergoing what she described as an “important test.” The Good ...

For Avadel’s Lumryz, the one-dose extended-release oral suspension that allows narcolepsy patients to sleep through the night, the worst-case scenario is it won't be on the market until 2025 ...